File manager - Edit - /home/aussies6/mail/cur/1604348084.M342799P5459.au6.voltdns.com,S=58261,W=59848:2,
Back
Return-Path: <bounce-34353_HTML-1145078351-56268-7293150-231038@bounce.s7.exacttarget.com> Delivered-To: aussies6@au6.voltdns.com Received: from au6.voltdns.com by au6.voltdns.com with LMTP id cOPjE7RooF9TFQAATr7HEg (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-231038@bounce.s7.exacttarget.com>) for <aussies6@au6.voltdns.com>; Tue, 03 Nov 2020 06:14:44 +1000 Return-path: <bounce-34353_HTML-1145078351-56268-7293150-231038@bounce.s7.exacttarget.com> Envelope-to: ian.hamilton@aussieseafoodhouse.com.au Delivery-date: Tue, 03 Nov 2020 06:14:44 +1000 Received: from df108.mta.exacttarget.com ([13.111.2.108]:55252) by au6.voltdns.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.93) (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-231038@bounce.s7.exacttarget.com>) id 1kZgDw-0001Nh-KM for ian.hamilton@aussieseafoodhouse.com.au; Tue, 03 Nov 2020 06:14:44 +1000 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; s=200608; d=primarymarkets.com; h=Message-ID:Date:Subject:From:To:MIME-Version:Content-Type: List-Unsubscribe-Post:List-Unsubscribe:List-ID:X-CSA-Complaints; i=james.green@primarymarkets.com; bh=88L1hm9m2uhAroQ+N54a4WmMnzuTAUL5xt5E2lQwAZU=; b=Eme0+VrlmP/kyDa1W0cg8RCIzY81g8I50/6DV8L1TiwGcRmtcdWilnv/+SaWFCl507xUOF+4J/W5 opFYSgDYfqFYqWzSVWRJadxkpjj70tl3T5ckXUeZlUsHaINf9206xKC0epqvCbK3FG6r4pM3KJKe DZWI9s5jDFMc+Jm1toU= Received: by df108.mta.exacttarget.com id hk1kb02fmd49 for <ian.hamilton@aussieseafoodhouse.com.au>; Mon, 2 Nov 2020 20:13:58 +0000 (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-231038@bounce.s7.exacttarget.com>) X-Virus-Scanned: amavisd-new at orionsmtp-227.s7.exacttarget.com Message-ID: <a4b7a9cb-6a65-4cdb-811c-a12a851e8d6f@atl1s07mta3016.xt.local> Date: Mon, 02 Nov 2020 14:13:58 -0600 Subject: PrimaryMarkets Trading From: James Green <james.green@primarymarkets.com> To: ian.hamilton@aussieseafoodhouse.com.au MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="_=_swift_v4_1604347796_b6fd3a76287d76c950eb1348638eb95c_=_" X-Source-Ref-Id: 790120519 List-Unsubscribe-Post: List-Unsubscribe=One-Click List-Unsubscribe: <https://go.primarymarkets.com/listUnsubscribeHeader/u/279962/5dff1c304acd87442e0e3cb4b28c05bf8dda3de5195055ab75548c39ef116cbe/790120519> X-Report-Abuse-To: abuse@pd25.com X-Pardot-Route: 144:279962:790120519 List-ID: <7293150_56268.xt.local> X-CSA-Complaints: whitelistcomplaints@eco.de x-job: 7293150_56268 X-Spam-Status: No, score=0.3 X-Spam-Score: 3 X-Spam-Bar: / X-Ham-Report: Spam detection software, running on the system "au6.voltdns.com", has NOT identified this incoming email as spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see root\@localhost for details. Content preview: Latest Opportunities on the PrimaryMarkets Global Platform https://go.primarymarkets.com/e/279962/2020-11-02/jykqb/790120519?h=xnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y Latest Opportunities on the PrimaryMarkets Global Platform Content analysis details: (0.3 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked. See http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block for more information. [URIs: primarymarkets.com] 0.1 INVESTMENT_ADVICE BODY: Message mentions investment advice 0.2 HEADER_FROM_DIFFERENT_DOMAINS From and EnvelopeFrom 2nd level mail domains are different -0.0 SPF_PASS SPF: sender matches SPF record 0.0 HTML_MESSAGE BODY: HTML included in message -0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's domain 0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid -0.1 DKIM_VALID Message has at least one valid DKIM or DK signature 0.0 LOTS_OF_MONEY Huge... sums of money X-Spam-Flag: NO --_=_swift_v4_1604347796_b6fd3a76287d76c950eb1348638eb95c_=_ Content-Type: text/plain; charset=utf-8 Content-Transfer-Encoding: quoted-printable Latest Opportunities on the PrimaryMarkets Global Platform https://go.= primarymarkets.com/e/279962/2020-11-02/jykqb/790120519?h=3DxnZ0hvMqSbU_vROf= M7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09=09=09=09=09=09=09=09=09=09Latest= Opportunities on the PrimaryMarkets Global Platform =09=09=09=09=09= =09=09=09=09=09=09=09Investor Centre =09=09=09=09=09=09=09=09=09=09=09= =09Company: Pharmaxis (ASX: PXS) Sector : Pharmaceutical Type: In= vestor Centre Description: Pharmaxis (ASX:PXS) announced the United St= ates Food and Drug Administration (FDA) has approved Bronchitol=C2=AE (mann= itol) as add-on maintenance therapy to improve pulmonary function in cystic= fibrosis (CF) patients 18 years of age and older. The product, developed b= y Pharmaxis in Australia, has been steered through final stages of FDA appr= oval by US licensee Chiesi Farmaceutici SpA (Chiesi). A US$7 million m= ilestone is now payable to Pharmaxis by Chiesi with a further US$3 million = payable on shipment by Pharmaxis of commercial launch stock scheduled for t= he first quarter of 2021. Pharmaxis also announced details of the clin= ical development plan for its lead drug pipeline asset being studied for th= e bone marrow cancer myelofibrosis. PXS-5505 has already received IND = approval and Orphan Drug Designation from the FDA and will proceed to an op= en label study recruiting up to 42 patients with myelofibrosis in Australia= and international sites. PXS-5505 is a pan-LOX inhibitor that seeks to rev= erse the bone marrow fibrosis that drives morbidity and mortality in the di= sease. PrimaryMarkets now operates an Investor Centre for Pharmaxis, a= dedicated online Platform to support investor awareness and market eductio= n. Read full releases: =09FDA Approves Bronchitol for US Market -= ASX Announcement https://go.primarymarkets.com/e/279962/hitol-FDA-ASX= -Announcement-pdf/jykqd/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77= rc2J7Y =09Pharamaxis Prioritises Breakthrough Clinical Program on Myel= ofibrosis https://go.primarymarkets.com/e/279962/PXS-MF-550520MYELOFIB= ROSIS-pdf/jykqg/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y= =09FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis = https://go.primarymarkets.com/e/279962/ronchitol-FDA-and-MF-Trial-pdf/jykqj= /790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09= =09=09=09=09=09=09=09=09=09=09=09=09Visit the Pharmaxis Investor Centre = =E2=86=92 https://go.primarymarkets.com/e/279962/custom-pharmaxis-home= -page/jykql/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y = =09=09=09=09=09=09=09=09=09=09=09=09Property Fund =09=09=09=09=09=09= =09=09=09=09=09=09Company: Pallas Capital =09=09=09=09=09=09=09=09=09= =09=09=09Sector : Property =09=09=09=09=09=09=09=09=09=09=09=09Type: S= ecured Bond =09=09=09=09=09=09=09=09=09=09=09=09Description: Pallas Ca= pital is a specialist commercial real estate financier and investment mana= ger and a wholly owned subsidiary of Pallas Group. Established in 2016, Pal= las specialises in the provision of structured debt and equity products to = well-seasoned Australian real estate asset owners and developers, providing= excellent risk adjusted returns to its investor base. =09=09=09=09=09= =09=09=09=09=09=09=09Pallas Capital employs 18 dedicated real estate profes= sional staff across its Sydney and Melbourne offices. =09=09=09=09=09= =09=09=09=09=09=09=09Pallas has an impeccable track record providing in exc= ess of A$415m total investments since inception across 73 debt and equity t= ransactions (55 debt) and a range of real estate sectors, currently totalli= ng in excess of A$260million in single asset and diversified trusts Funds U= nder Management (FUM) as at 30 September 2020. Of those 73 transactions, 39= are first mortgages that have delivered an average net return of 9.4% pa.= =09=09=09=09=09=09=09=09=09=09=09=09Pallas Capital is raising up to A= $100m; initial issue c.A$30m. A fixed coupon of 7.5% p.a. is payable over a= 4 year term in denominations of A$10,000. =09=09=09=09=09=09=09=09=09= =09=09=09=09=09=09Learn more about Pallas Capital Investing =E2=86=92 = https://go.primarymarkets.com/e/279962/assets-on-offer-pallas-capital/jykqn= /790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09= =09=09=09=09=09=09=09=09=09Capital Raise =09=09=09=09=09=09=09=09=09= =09=09=09Company: GMDx Genomics =09=09=09=09=09=09=09=09=09=09=09=09Se= ctor : Genome Healthcare =09=09=09=09=09=09=09=09=09=09=09=09Type: Pri= mary Equity Raise =09=09=09=09=09=09=09=09=09=09=09=09Business Update:= GMDx is well advanced in a current study with The CRC for Mental Health (w= hich includes The Florey Institute, The CSIRO and several others) regarding= the early detection of Alzheimer=E2=80=99s disease. This study has been un= dertaken in order to validate an important GMDx genomic application and bui= ld on the very successful proof of concept completed by GMDx in 2019 in thi= s area. This study is expected to be completed prior to the end of 2020. = =09=09=09=09=09=09=09=09=09=09=09=09=20 =09=09=09=09=09=09=09=09= =09=09=09=09The first GMDx patent application in relation to cognitive impa= irment (including Alzheimer=E2=80=99s and other neurodegenerative disorders= ) was lodged by the company in 2019.=20 =09=09=09=09=09=09=09=09=09=09= =09=09=20 =09=09=09=09=09=09=09=09=09=09=09=09In additional to the curre= nt research and development for genomic applications in Cognitive Impairmen= t and Oncology, GMDx has now partnered with Oracle to provide Genomic Data = Services to the wider market. This undertaking will provide GMDx customers = and collaborators with access to a new generation of genomic analytics to e= nhance research and development capabilities, drug discovery and developmen= t and clinical trials.=20 =09=09=09=09=09=09=09=09=09=09=09=09Descriptio= n: GMDx is a genomics testing company that delivers the next generation of = immunogenomic diagnostics in oncology. GMDx was established in 2015 to furt= her develop and commercialise the discoveries of Dr Robyn Lindley. GMDx has= developed a comprehensive and powerful genomic-profile testing platform wi= th the clinical applications in oncology for: =20 =09=09=09=09=09=09=09= =09=09=09=09=09=09predicting patient response to immunotherapy treatment an= d =09=09=09=09=09=09=09=09=09=09=09=09=09predicting cancer progression= . =09=09=09=09=09=09=09=09=09=09=09=09The GMDx platform technology com= bines proprietary predictive algorithms, a strong and extensive IP portfoli= o, sophisticated analytics and machine learning capabilities that provide c= ustomers with clinical grade whole genome testing. =09=09=09=09=09=09= =09=09=09=09=09=09GMDx is an Australian company raising A$1.7M. =09=09= =09=09=09=09=09=09=09=09=09=09=09=09=09GMDx Capital Raise =E2=86=92 ht= tps://go.primarymarkets.com/e/279962/assets-on-offer-gmdx-group-ltd/jykqq/7= 90120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09=09= =09=09=09=09=09=09=09=09This email is intended for Accredited/Sophisticated= /Wholesale investors only. By accepting this email you are self-accrediting= that you so qualify. =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09TRA= DING HUBS https://go.primarymarkets.com/e/279962/trading-hubs/jykqs/79= 0120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09=09= =09=09=09=09=09=09=09=09=09=09=09SECONDARY TRADING https://go.primarym= arkets.com/e/279962/secondary-trading-2/jykqv/790120519?h=3DxnZ0hvMqSbU_vRO= fM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09=09=09=09=09=09=09=09=09=09=09= =09=09CAPITAL RAISES https://go.primarymarkets.com/e/279962/current-of= ferings/jykqx/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y = =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09UNICORNS https://go.pr= imarymarkets.com/e/279962/buy-shares-in-unicorns/jykqz/790120519?h=3DxnZ0hv= MqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =09=09=09=09=09=09Connect with U= s: https://go.primarymarkets.com/e/279962/PrimaryMarkets/jykr2/7901205= 19?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =20 https://go.p= rimarymarkets.com/e/279962/Primary-Markets/jykr4/790120519?h=3DxnZ0hvMqSbU_= vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y =20 https://go.primarymarkets.com/e= /279962/company-primarymarkets/jykr6/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0Z= IWS1ALv19VE77rc2J7Y https://go.primarymarkets.com/e/279962/edium-email= -utm-content-footer/jykr8/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE= 77rc2J7Y =09=09=09=09=09=09+61 2 9993 4475 =09=09=09=09=09=09www.= primarymarkets.com https://go.primarymarkets.com/e/279962/edium-email-= utm-content-footer/jykr8/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE7= 7rc2J7Y =09=09=09=09=09=09Corporate Authorised Representative: AFSL 33= 4 838 =09=09=09=09=09=09Level 16, 56 Pitt Street, Sydney NSW 2000, Aus= tralia =09=09=09=09=09=09PO Box R697, Royal Exchange NSW 1225, Austral= ia =09=09=09=09=09=09IMPORTANT LEGAL NOTICE AND DISCLOSURES: Nothing c= ontained in this email constitutes tax, legal, insurance or investment advi= ce nor does it constitute a solicitation or an offer to buy or sell any sec= urity or other financial instrument. This email and any attachment(s) are i= ntended only for the exclusive use of the addressee(s) and may contain info= rmation that is privileged and confidential. If you are not the intended re= cipient, any use, interference with, disclosure or copying of this material= is unauthorised and strictly prohibited. If you have received this message= in error, please notify the sender by return email immediately and delete = the message from your computer without making any copies. Investing in secu= rities in private companies is speculative and involves a high degree of ri= sk. The recipient must be prepared to withstand a total loss of your invest= ment. We strongly encourage the recipient to complete their own independent= due diligence before investing in securities or financial instruments incl= uding obtaining additional information, opinions, financial projections and= legal or other investment advice. All emails sent to or from PrimaryMarket= s Limited corporate email systems may be retained, monitored and/or reviewe= d by PrimaryMarkets and its respective personnel. =09=09=09=09=09=09Te= rms, Privacy and Legal https://go.primarymarkets.com/e/279962/edium-em= ail-utm-content-footer/jykrb/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv1= 9VE77rc2J7Y | Unsubscribe=20 https://go.primarymarkets.com/unsubs= cribe/u/279962/5dff1c304acd87442e0e3cb4b28c05bf8dda3de5195055ab75548c39ef11= 6cbe/790120519 --_=_swift_v4_1604347796_b6fd3a76287d76c950eb1348638eb95c_=_ Content-Type: text/html; charset=utf-8 Content-Transfer-Encoding: quoted-printable <!DOCTYPE html> <html lang=3D"en"> <head> <title>PrimaryMarkets = Email update</title> <meta http-equiv=3D"Content-Type" content=3D= "text/html; charset=3Dutf-8" /> <meta name=3D"viewport" content=3D"widt= h=3Ddevice-width, initial-scale=3D1"> <meta http-equiv=3D"X-UA-Compatib= le" content=3D"IE=3Dedge" /> <style type=3D"text/css"> /* CLIENT-= SPECIFIC STYLES */ #outlook a { padding: 0; } = /* Force Outlook to provide a "view in browser" message */ .ReadMsgBo= dy { width: 100%; } .ExternalClass { width: = 100%; } /* Force Hotmail to display emails at full width */= .ExternalClass, .ExternalClass p, .ExternalClass span,= .ExternalClass font, .ExternalClass td, .ExternalClass d= iv { line-height: 100%; } /* Force Hotmail to displa= y normal line spacing */ body, table, td, a { = -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; = } /* Prevent WebKit and Windows mobile changing default text siz= es */ table, td { mso-table-lspace: 0pt; mso-ta= ble-rspace: 0pt; } /* Remove spacing between tables in Outlo= ok 2007 and up */ img { -ms-interpolation-mode: bicubic; = } /* Allow smoother rendering of resized image in Internet Explo= rer */ /* RESET STYLES */ body { margin: 0; = padding: 0; } img { border: 0; height: auto;= line-height: 100%; outline: none; text-decoration:= none; } table { border-collapse: collapse !importan= t; } body { height: 100% !important; margin:= 0; padding: 0; width: 100% !important; } /*= iOS BLUE LINKS */ .appleBody a { color: #68440a; tex= t-decoration: none; } .appleFooter a { color: #99999= 9; text-decoration: none; } /* MOBILE STYLES */ = @media screen and (max-width: 525px) { /* ALLOWS FOR FLUID TAB= LES */ table[class=3D"wrapper"] { width: 100% !important;= } /* ADJUSTS LAYOUT OF LOGO IMAGE */ td[class= =3D"logo"] { text-align: left; padding: 20px 0 10px 0 != important; } td[class=3D"logo"] img { margin: = 0 auto !important; } /* USE THESE CLASSES TO HIDE CONTEN= T ON MOBILE */ td[class=3D"mobile-hide"] { display: none;= } img[class=3D"mobile-hide"] { display: none = !important; } img[class=3D"img-max"] { max-wid= th: 100% !important; height: auto !important; } = /*USED TO ADJUST THE BANNER TEXT SIZE ON MOBILE */ td[class= =3D"banner-mobile"] { font-size: 16px !important; } = /* FULL-WIDTH TABLES */ table[class=3D"responsive-table"] {= width: 100% !important; } /* UTILITY CLASSES = FOR ADJUSTING PADDING ON MOBILE */ td[class=3D"padding"] { = padding: 10px 5% 15px 5% !important; } td[class=3D"pad= ding-copy"] { padding: 10px 5% 15px 5% !important; text= -align: center; } td[class=3D"padding-meta"] { = padding: 30px 5% 0px 5% !important; text-align: center; = } td[class=3D"no-pad"] { padding: 0 0 20px 0 !importan= t; } td[class=3D"no-padding"] { padding: 0 !im= portant; } td[class=3D"section-padding"] { pad= ding: 20px 15px 20px 15px !important; } td[class=3D"sect= ion-padding-bottom-image"] { padding: 20px 15px 0 15px !important= ; } /* ADJUST BUTTONS ON MOBILE */ td[class=3D"m= obile-wrapper"] { padding: 10px 5% 15px 5% !important; }= table[class=3D"mobile-button-container"] { margin: 0 = auto; width: 100% !important; } a[class=3D"mob= ile-button"] { width: 80% !important; padding: 15px !im= portant; border: 0 !important; font-size: 16px !importa= nt; } } </style> </head> <body style=3D"margin:= 0; padding: 0;"> <!-- Some preview text. --> <div class=3D"litmus-buil= der-preview-text" style=3D"display:none;font-size:1px;color:#333333;line-he= ight:1px;max-height:0px;max-width:0px;opacity:0;overflow:hidden;">Latest Op= portunities on the PrimaryMarkets Global Platform</div> <!-- HEADER -->= <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"prese= ntation" width=3D"100%"> =09<tbody> =09=09<tr> =09=09=09<td bgcolor= =3D"#ffffff"> =09=09=09<div align=3D"center" style=3D"padding: 0px 15px 0= px 15px;"> =09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"= 0" class=3D"wrapper" role=3D"presentation" width=3D"500"><!-- LOGO/PREHEADE= R TEXT --> =09=09=09=09<tbody> =09=09=09=09=09<tr> =09=09=09=09=09=09= <td class=3D"logo" style=3D"padding: 20px 0px 10px 0px;"> =09=09=09=09=09= =09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presenta= tion" width=3D"100%"> =09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09= =09=09<tr> =09=09=09=09=09=09=09=09=09<td align=3D"left" bgcolor=3D"#ffff= ff" width=3D"100"><a href=3D"https://go.primarymarkets.com/e/279962/2020-11= -02/jykqb/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" target= =3D"_blank"><img alt=3D"PrimaryMarkets" border=3D"0" height=3D"78" src=3D"h= ttps://www.primarymarkets.com/images/favicon/apple-icon-120x120.png" style= =3D"display: block; font-family: Calibri,sans-serif; color: #666666; font-s= ize: 16px;" width=3D"52"></a></td> =09=09=09=09=09=09=09=09=09<td align= =3D"right" bgcolor=3D"#ffffff" width=3D"400"> =09=09=09=09=09=09=09=09=09= <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presentatio= n"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09= =09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"right" class= =3D"banner-mobile" style=3D"padding: 0 0 5px 0; font-size: 18px; font-famil= y: Arial, sans-serif; color: #666666; text-decoration: none;">Latest Opport= unities on the <span style=3D"color:#27ae60;">PrimaryMarkets</span>&nb= sp;Global Platform</td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09= =09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table> = =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09= =09=09=09=09=09</tbody> =09=09=09=09=09=09</table> =09=09=09=09=09=09</= td> =09=09=09=09=09</tr> =09=09=09=09</tbody> =09=09=09</table> =09= =09=09</div> =09=09=09</td> =09=09</tr> =09</tbody> </table> <!--= ONE COLUMN SECTION --> <table border=3D"0" cellpadding=3D"0" cellspac= ing=3D"0" class=3D"content" pardot-repeatable=3D"" role=3D"presentation" wi= dth=3D"100%"> =09<tbody> =09=09<tr> =09=09=09<td align=3D"center" bgc= olor=3D"#ffffff" class=3D"section-padding" style=3D"padding: 10px 15px 0px = 15px;"> =09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" = class=3D"responsive-table" role=3D"presentation" width=3D"500"> =09=09=09= =09<tbody> =09=09=09=09=09<tr> =09=09=09=09=09=09<td> =09=09=09=09=09= =09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presenta= tion" style=3D"border-top:1px solid #777;" width=3D"100%"> =09=09=09=09= =09=09=09<tbody> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09= =09<td><!-- HERO IMAGE --> =09=09=09=09=09=09=09=09=09<table border=3D"0"= cellpadding=3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%">= =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09= =09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td class=3D"padding-copy" st= yle=3D"padding: 10px 0 0 0;"> =09=09=09=09=09=09=09=09=09=09=09=09<table = border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presentation" widt= h=3D"100%"> =09=09=09=09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09= =09=09=09=09=09=09=09=09=09=09<tr style=3D""> =09=09=09=09=09=09=09=09=09= =09=09=09=09=09=09<td align=3D"center" pardot-region=3D"main-text-01"><img = alt=3D"" border=3D"0" class=3D"img-max" height=3D"50" src=3D"https://primar= ymarket.worldsecuresystems.com/images/Logos/Pharmaxis%20200%20x%2050.png" s= tyle=3D"display: block; padding: 0px; color: rgb(102, 102, 102); text-decor= ation: none; font-family: Calibri, sans-serif; font-size: 16px; border-widt= h: 0px; border-style: solid; width: 200px; height: 50px;" width=3D"200"></t= d> =09=09=09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09= =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table= > =09=09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09= =09=09=09</table> =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td= ><!-- COPY --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09= =09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<tr style= =3D""> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"left" class=3D"pa= dding-copy" pardot-region=3D"main-text-01" pardot-region-type=3D"WYSIWYG" s= tyle=3D"font-family:Calibri,sans-serif;color:#27ae60;font-size:18px; line-h= eight:1.6; padding-top: 10px;"><font color=3D"#2ecc71">Investor Centre</fon= t></td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09= =09=09=09<tr style=3D""> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D= "left" class=3D"padding-copy" pardot-region=3D"main-text-01" pardot-region-= type=3D"WYSIWYG" style=3D"font-family:Calibri,sans-serif;color:#000000;font= -size:14px; line-height:1.6; padding-top: 0px;"><strong>Company:</strong>&n= bsp;Pharmaxis (ASX: PXS)<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>= Sector : </strong>Pharmaceutical<br> =09=09=09=09=09=09=09=09=09=09=09=09= <strong>Type:</strong> Investor Centre<br> =09=09=09=09=09=09=09=09= =09=09=09=09<strong>Description:</strong> <b>Pharmaxis (ASX:PXS) = </b>announced the United States Food and Drug Administration (FDA) has appr= oved Bronchitol=C2=AE (mannitol) as add-on maintenance therapy to improve p= ulmonary function in cystic fibrosis (CF) patients 18 years of age and olde= r. The product, developed by Pharmaxis in Australia, has been steered throu= gh final stages of FDA approval by US licensee Chiesi Farmaceutici SpA (Chi= esi).<br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09=09=09=09=09=09= =09=09=09=09=09=09A US$7 million milestone is now payable to Pharmaxis by C= hiesi with a further US$3 million payable on shipment by Pharmaxis of comme= rcial launch stock scheduled for the first quarter of 2021.<br> =09=09=09= =09=09=09=09=09=09=09=09=09<br> =09=09=09=09=09=09=09=09=09=09=09=09Pharm= axis also announced details of the clinical development plan for its lead d= rug pipeline asset being studied for the bone marrow cancer myelofibrosis.<= br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09=09=09=09=09=09=09=09= =09=09=09=09PXS-5505 has already received IND approval and Orphan Drug Desi= gnation from the FDA and will proceed to an open label study recruiting up = to 42 patients with myelofibrosis in Australia and international sites. PXS= -5505 is a pan-LOX inhibitor that seeks to reverse the bone marrow fibrosis= that drives morbidity and mortality in the disease.<br> =09=09=09=09=09= =09=09=09=09=09=09=09<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>Pri= maryMarkets</strong> now operates an Investor Centre for <strong>Pharmaxis<= /strong>, a dedicated online Platform to support investor awareness and mar= ket eduction.<br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09=09=09=09= =09=09=09=09=09=09=09=09Read full releases: =09=09=09=09=09=09=09=09=09= =09=09=09<ul> =09=09=09=09=09=09=09=09=09=09=09=09=09<li><a href=3D"https= ://go.primarymarkets.com/e/279962/hitol-FDA-ASX-Announcement-pdf/jykqd/7901= 20519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" target=3D"_blank">FD= A Approves Bronchitol for US Market - ASX Announcement</a></li> =09=09=09= =09=09=09=09=09=09=09=09=09=09<li><a href=3D"https://go.primarymarkets.com/= e/279962/PXS-MF-550520MYELOFIBROSIS-pdf/jykqg/790120519?h=3DxnZ0hvMqSbU_vRO= fM7X2xm0ZIWS1ALv19VE77rc2J7Y" target=3D"_blank">Pharamaxis Prioritises Brea= kthrough Clinical Program on Myelofibrosis</a></li> =09=09=09=09=09=09=09= =09=09=09=09=09=09<li><a href=3D"https://go.primarymarkets.com/e/279962/ron= chitol-FDA-and-MF-Trial-pdf/jykqj/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS= 1ALv19VE77rc2J7Y" target=3D"_blank">FDA Bronchitol Approval to Generate Cas= h Flows for Pharmaxis</a></li> =09=09=09=09=09=09=09=09=09=09=09=09</ul>= =09=09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09= =09=09=09</table> =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td= ><!-- BULLETPROOF BUTTON --> =09=09=09=09=09=09=09=09=09<table border=3D"= 0" cellpadding=3D"0" cellspacing=3D"0" class=3D"mobile-button-container" ro= le=3D"presentation" width=3D"100%"> =09=09=09=09=09=09=09=09=09=09<tbody>= =09=09=09=09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09= =09=09<td align=3D"center" class=3D"padding-copy" style=3D"padding: 25px 0 = 30px 0;"> =09=09=09=09=09=09=09=09=09=09=09=09<table border=3D"0" cellpad= ding=3D"0" cellspacing=3D"0" class=3D"responsive-table" role=3D"presentatio= n"> =09=09=09=09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09= =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09=09=09= =09<td align=3D"center"><a class=3D"mobile-button" href=3D"https://go.prima= rymarkets.com/e/279962/custom-pharmaxis-home-page/jykql/790120519?h=3DxnZ0h= vMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" pardot-region=3D"button" style=3D"f= ont-size: 16px; font-family: Calibri,sans-serif; font-weight: normal; color= : #ffffff; text-decoration: none; background-color: #e97721; border-top: 15= px solid #e97721; border-bottom: 15px solid #e97721; border-left: 25px soli= d #e97721; border-right: 25px solid #e97721; border-radius: 3px; -webkit-bo= rder-radius: 3px; -moz-border-radius: 3px; display: inline-block;" target= =3D"_blank">Visit the Pharmaxis Investor Centre =E2=86=92</a></td> =09=09= =09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09= =09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table> =09=09= =09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09</tr= > =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</t= able> =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> = =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09</table> =09=09=09=09= =09=09</td> =09=09=09=09=09</tr> =09=09=09=09</tbody> =09=09=09</tabl= e> =09=09=09</td> =09=09</tr> =09</tbody> </table> <!-- ONE COLUM= N SECTION --> <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" = class=3D"content" pardot-repeatable=3D"" role=3D"presentation" width=3D"100= %"> =09<tbody> =09=09<tr> =09=09=09<td align=3D"center" bgcolor=3D"#f= fffff" class=3D"section-padding" style=3D"padding: 10px 15px 0px 15px;"> = =09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" class=3D"r= esponsive-table" role=3D"presentation" width=3D"500"> =09=09=09=09<tbody>= =09=09=09=09=09<tr> =09=09=09=09=09=09<td> =09=09=09=09=09=09<table = border=3D"0" cellpadding=3D"0" cellspacing=3D"0" role=3D"presentation" styl= e=3D"border-top:1px solid #777;" width=3D"100%"> =09=09=09=09=09=09=09<tb= ody> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- H= ERO IMAGE --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09= =09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<tr> =09= =09=09=09=09=09=09=09=09=09=09=09<td class=3D"padding-copy" style=3D"paddin= g: 10px 0 0 0;"> =09=09=09=09=09=09=09=09=09=09=09=09<table border=3D"0" = cellpadding=3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%">= =09=09=09=09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09= =09=09=09=09=09=09=09<tr style=3D""> =09=09=09=09=09=09=09=09=09=09=09=09= =09=09=09<td align=3D"center" pardot-region=3D"main-text-01"><img alt=3D"" = border=3D"0" class=3D"img-max" height=3D"150" src=3D"https://primarymarket.= worldsecuresystems.com/images/Logos/Pallas%20200%20x%20150.png" style=3D"di= splay: block; padding: 0px; color: rgb(102, 102, 102); text-decoration: non= e; font-family: Calibri, sans-serif; font-size: 16px; width: 200px; height:= 150px; border-width: 0px; border-style: solid;" width=3D"200"></td> =09= =09=09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09= =09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table> =09= =09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09<= /tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09= </table> =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr>= =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- COPY = --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cell= spacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09=09=09=09=09= =09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<tr style=3D""> =09= =09=09=09=09=09=09=09=09=09=09=09<td align=3D"left" class=3D"padding-copy" = pardot-region=3D"main-text-01" pardot-region-type=3D"WYSIWYG" style=3D"font= -family:Calibri,sans-serif;color:#000000;font-size:18px; line-height:1.6; p= adding-top: 10px;"><span style=3D"color:#2ecc71;">Property Fund</span></td>= =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09= =09<tr style=3D""> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"left"= class=3D"padding-copy" pardot-region=3D"main-text-01" pardot-region-type= =3D"WYSIWYG" style=3D"font-family:Calibri,sans-serif;color:#000000;font-siz= e:14px; line-height:1.6; padding-top: 0px;"><strong>Company:</strong> = Pallas Capital<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>Sector : <= /strong>Property<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>Type:</s= trong> Secured Bond<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>= Description:</strong> <strong>Pallas Capital</strong> is a = specialist commercial real estate financier and investment manager and a wh= olly owned subsidiary of Pallas Group. Established in 2016, Pallas speciali= ses in the provision of structured debt and equity products to well-seasone= d Australian real estate asset owners and developers, providing excellent r= isk adjusted returns to its investor base.<br> =09=09=09=09=09=09=09=09= =09=09=09=09<br> =09=09=09=09=09=09=09=09=09=09=09=09Pallas Capital emplo= ys 18 dedicated real estate professional staff across its Sydney and Melbou= rne offices.<br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09=09=09=09= =09=09=09=09=09=09=09=09Pallas has an impeccable track record providing in = excess of A$415m total investments since inception across 73 debt and equit= y transactions (55 debt) and a range of real estate sectors, currently tota= lling in excess of A$260million in single asset and diversified trusts Fund= s Under Management (FUM) as at 30 September 2020. Of those 73 transactions,= 39 are first mortgages that have delivered an average net return of 9.4% p= a.<br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09=09=09=09=09=09=09= =09=09=09=09=09Pallas Capital is raising up to A$100m; initial issue c.A$30= m. A fixed coupon of 7.5% p.a. is payable over a 4 year term in denominatio= ns of A$10,000.</td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table> =09= =09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- BULLETPROOF BUTTO= N --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" ce= llspacing=3D"0" class=3D"mobile-button-container" role=3D"presentation" wid= th=3D"100%"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09= =09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"cent= er" class=3D"padding-copy" style=3D"padding: 25px 0 30px 0;"> =09=09=09= =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspacin= g=3D"0" class=3D"responsive-table" role=3D"presentation"> =09=09=09=09=09= =09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09=09=09= =09<tr> =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center"= ><a class=3D"mobile-button" href=3D"https://go.primarymarkets.com/e/279962/= assets-on-offer-pallas-capital/jykqn/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0Z= IWS1ALv19VE77rc2J7Y" pardot-region=3D"button" style=3D"font-size: 16px; fon= t-family: Calibri,sans-serif; font-weight: normal; color: #ffffff; text-dec= oration: none; background-color: #e97721; border-top: 15px solid #e97721; b= order-bottom: 15px solid #e97721; border-left: 25px solid #e97721; border-r= ight: 25px solid #e97721; border-radius: 3px; -webkit-border-radius: 3px; -= moz-border-radius: 3px; display: inline-block;" target=3D"_blank">Learn mor= e about Pallas Capital Investing =E2=86=92</a></td> =09=09=09=09=09=09=09= =09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09=09=09=09</tbody= > =09=09=09=09=09=09=09=09=09=09=09=09</table> =09=09=09=09=09=09=09=09= =09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09= =09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table> =09=09= =09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09=09=09= =09=09=09</tbody> =09=09=09=09=09=09</table> =09=09=09=09=09=09</td> = =09=09=09=09=09</tr> =09=09=09=09</tbody> =09=09=09</table> =09=09=09= </td> =09=09</tr> =09</tbody> </table> <!-- ONE COLUMN SECTION -->= <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" class=3D"cont= ent" pardot-repeatable=3D"" role=3D"presentation" width=3D"100%"> =09<tbo= dy> =09=09<tr> =09=09=09<td align=3D"center" bgcolor=3D"#ffffff" class= =3D"section-padding" style=3D"padding: 10px 15px 0px 15px;"> =09=09=09<ta= ble border=3D"0" cellpadding=3D"0" cellspacing=3D"0" class=3D"responsive-ta= ble" role=3D"presentation" width=3D"500"> =09=09=09=09<tbody> =09=09=09= =09=09<tr> =09=09=09=09=09=09<td> =09=09=09=09=09=09<table border=3D"0"= cellpadding=3D"0" cellspacing=3D"0" role=3D"presentation" style=3D"border-= top:1px solid #777;" width=3D"100%"> =09=09=09=09=09=09=09<tbody> =09= =09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- HERO IMAGE = --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cell= spacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09=09=09=09=09= =09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<tr> =09=09=09=09=09= =09=09=09=09=09=09=09<td class=3D"padding-copy" style=3D"padding: 10px 0 0 = 0;"> =09=09=09=09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09= =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09= =09=09=09<tr style=3D""> =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td= align=3D"center" pardot-region=3D"main-text-01"><img alt=3D"" border=3D"0"= class=3D"img-max" height=3D"100" src=3D"https://primarymarket.worldsecures= ystems.com/images/Logos/GMDx%20200%20x%20100.png" style=3D"display: block; = padding: 0px; color: rgb(102, 102, 102); text-decoration: none; font-family= : Calibri, sans-serif; font-size: 16px; border-width: 0px; border-style: so= lid; width: 200px; height: 100px;" width=3D"200"></td> =09=09=09=09=09=09= =09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09=09=09=09</tb= ody> =09=09=09=09=09=09=09=09=09=09=09=09</table> =09=09=09=09=09=09=09= =09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table> =09= =09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- COPY --> =09=09= =09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0= " role=3D"presentation" width=3D"100%"> =09=09=09=09=09=09=09=09=09=09<tb= ody> =09=09=09=09=09=09=09=09=09=09=09<tr style=3D""> =09=09=09=09=09= =09=09=09=09=09=09=09<td align=3D"left" class=3D"padding-copy" pardot-regio= n=3D"main-text-01" pardot-region-type=3D"WYSIWYG" style=3D"font-family:Cali= bri,sans-serif;color:#000000;font-size:18px; line-height:1.6; padding-top: = 10px;"><span style=3D"color:#2ecc71;">Capital Raise</span></td> =09=09=09= =09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09=09<tr style= =3D""> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"left" class=3D"pa= dding-copy" pardot-region=3D"main-text-01" pardot-region-type=3D"WYSIWYG" s= tyle=3D"font-family:Calibri,sans-serif;color:#000000;font-size:14px; line-h= eight:1.6; padding-top: 0px;"><strong>Company:</strong> GMDx Genomics<= br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>Sector : </strong>Genome = Healthcare<br> =09=09=09=09=09=09=09=09=09=09=09=09<strong>Type:</strong>= Primary Equity Raise<br> =09=09=09=09=09=09=09=09=09=09=09=09<stron= g>Business Update:</strong> <strong>GMDx </strong>is well advanced in = a current study with The CRC for Mental Health (which includes The Florey I= nstitute, The CSIRO and several others) regarding the early detection of Al= zheimer=E2=80=99s disease. This study has been undertaken in order to valid= ate an important GMDx genomic application and build on the very successful = proof of concept completed by GMDx in 2019 in this area. This study is expe= cted to be completed prior to the end of 2020. <br> =09=09=09=09=09= =09=09=09=09=09=09=09 <br> =09=09=09=09=09=09=09=09=09=09=09=09The f= irst GMDx patent application in relation to cognitive impairment (including= Alzheimer=E2=80=99s and other neurodegenerative disorders) was lodged by t= he company in 2019. <br> =09=09=09=09=09=09=09=09=09=09=09=09 <= br> =09=09=09=09=09=09=09=09=09=09=09=09In additional to the current rese= arch and development for genomic applications in Cognitive Impairment and O= ncology, GMDx has now partnered with Oracle to provide Genomic Data Service= s to the wider market. This undertaking will provide GMDx customers and col= laborators with access to a new generation of genomic analytics to enhance = research and development capabilities, drug discovery and development and c= linical trials. <br> =09=09=09=09=09=09=09=09=09=09=09=09<br> =09= =09=09=09=09=09=09=09=09=09=09=09Description: GMDx is a genomics testing co= mpany that delivers the next generation of immunogenomic diagnostics in onc= ology. GMDx was established in 2015 to further develop and commercialise th= e discoveries of Dr Robyn Lindley. GMDx has developed a comprehensive and p= owerful genomic-profile testing platform with the clinical applications in = oncology for: =09=09=09=09=09=09=09=09=09=09=09=09<ul> =09=09=09= =09=09=09=09=09=09=09=09=09=09<li>predicting patient response to immunother= apy treatment and</li> =09=09=09=09=09=09=09=09=09=09=09=09=09<li>predict= ing cancer progression.</li> =09=09=09=09=09=09=09=09=09=09=09=09</ul> = =09=09=09=09=09=09=09=09=09=09=09=09The GMDx platform technology combines p= roprietary predictive algorithms, a strong and extensive IP portfolio, soph= isticated analytics and machine learning capabilities that provide customer= s with clinical grade whole genome testing.<br> =09=09=09=09=09=09=09=09= =09=09=09=09<br> =09=09=09=09=09=09=09=09=09=09=09=09GMDx is an Australia= n company raising A$1.7M.</td> =09=09=09=09=09=09=09=09=09=09=09</tr> = =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table= > =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09= =09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!-- BULLETPROOF= BUTTON --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D= "0" cellspacing=3D"0" class=3D"mobile-button-container" role=3D"presentatio= n" width=3D"100%"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09= =09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td align= =3D"center" class=3D"padding-copy" style=3D"padding: 25px 0 30px 0;"> =09= =09=09=09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cell= spacing=3D"0" class=3D"responsive-table" role=3D"presentation"> =09=09=09= =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09= =09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"c= enter"><a class=3D"mobile-button" href=3D"https://go.primarymarkets.com/e/2= 79962/assets-on-offer-gmdx-group-ltd/jykqq/790120519?h=3DxnZ0hvMqSbU_vROfM7= X2xm0ZIWS1ALv19VE77rc2J7Y" pardot-region=3D"button" style=3D"font-size: 16p= x; font-family: Calibri,sans-serif; font-weight: normal; color: #ffffff; te= xt-decoration: none; background-color: #e97721; border-top: 15px solid #e97= 721; border-bottom: 15px solid #e97721; border-left: 25px solid #e97721; bo= rder-right: 25px solid #e97721; border-radius: 3px; -webkit-border-radius: = 3px; -moz-border-radius: 3px; display: inline-block;" target=3D"_blank">GMD= x Capital Raise =E2=86=92</a></td> =09=09=09=09=09=09=09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09= =09=09=09=09=09=09=09=09=09</table> =09=09=09=09=09=09=09=09=09=09=09=09<= /td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09= =09</tbody> =09=09=09=09=09=09=09=09=09</table> =09=09=09=09=09=09=09= =09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09</tbody>= =09=09=09=09=09=09</table> =09=09=09=09=09=09</td> =09=09=09=09=09</= tr> =09=09=09=09</tbody> =09=09=09</table> =09=09=09</td> =09=09</t= r> =09</tbody> </table> <!-- ONE COLUMN SECTION --> <table borde= r=3D"0" cellpadding=3D"0" cellspacing=3D"0" pardot-removable=3D"sign-off" r= ole=3D"presentation" width=3D"100%"> =09<tbody> =09=09<tr> =09=09=09<= td align=3D"center" bgcolor=3D"#f8f8f8" class=3D"section-padding-bottom-ima= ge" style=3D"padding: 40px 15px 0 15px;"> =09=09=09<table border=3D"0" ce= llpadding=3D"0" cellspacing=3D"0" class=3D"responsive-table" role=3D"presen= tation" width=3D"500"> =09=09=09=09<tbody> =09=09=09=09=09<tr> =09=09= =09=09=09=09<td> =09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" = cellspacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09=09=09=09= =09=09<tbody> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<= td><!-- COPY --> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpaddi= ng=3D"0" cellspacing=3D"0" role=3D"presentation" width=3D"100%"> =09=09= =09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<tr styl= e=3D""> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center" class=3D= "padding-copy" pardot-region=3D"sign-off-01" pardot-region-type=3D"WYSIWYG"= style=3D"padding: 20px 0 0 0; font-family:Calibri,sans-serif;color:#00000= 0;font-size:14px; line-height:1.6; ">This email is intended for Accredited/= Sophisticated/Wholesale investors only. By accepting this email you are sel= f-accrediting that you so qualify.</td> =09=09=09=09=09=09=09=09=09=09=09= </tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09= =09</table> =09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</= tr> =09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09<td><!--Tra= ding Hub Button--> =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpad= ding=3D"0" cellspacing=3D"0" class=3D"mobile-button-container" role=3D"pres= entation" width=3D"100%"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09= =09=09=09=09=09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td a= lign=3D"center" class=3D"padding-copy" style=3D"padding: 30px 0 10px 0;">= =09=09=09=09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0= " cellspacing=3D"0" class=3D"responsive-table" role=3D"presentation"> =09= =09=09=09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09= =09=09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td alig= n=3D"center"><a class=3D"mobile-button" href=3D"https://go.primarymarkets.c= om/e/279962/trading-hubs/jykqs/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1AL= v19VE77rc2J7Y" pardot-region=3D"button" style=3D"font-size: 12px; font-fami= ly: Calibri,sans-serif; font-weight: bold; color: #ffffff; text-decoration:= none; background-color: #00b366; border-top: 10px solid #00b366; border-bo= ttom: 10px solid #00b366; border-left: 40px solid #00b366; border-right: 40= px solid #00b366; border-radius: 5px; -webkit-border-radius: 5px; -moz-bord= er-radius: 5px; display: inline-block;" target=3D"_blank">TRADING HUBS</a><= /td> =09=09=09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09= =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table= > =09=09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09= =09=09</tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09= =09=09=09</table> =09=09=09=09=09=09=09=09=09<!--Trading Hub Button--> = =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspa= cing=3D"0" class=3D"mobile-button-container" role=3D"presentation" width=3D= "100%"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09= =09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center" cl= ass=3D"padding-copy" style=3D"padding: 0 0 10px 0;"> =09=09=09=09=09=09= =09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" c= lass=3D"responsive-table" role=3D"presentation"> =09=09=09=09=09=09=09=09= =09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09=09=09=09<tr> = =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center"><a class= =3D"mobile-button" href=3D"https://go.primarymarkets.com/e/279962/secondary= -trading-2/jykqv/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y"= pardot-region=3D"button" style=3D"font-size: 12px; font-family: Calibri,sa= ns-serif; font-weight: bold; color: #ffffff; text-decoration: none; backgro= und-color: #00b366; border-top: 10px solid #00b366; border-bottom: 10px sol= id #00b366; border-left: 18px solid #00b366; border-right: 18px solid #00b3= 66; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px= ; display: inline-block;" target=3D"_blank">SECONDARY TRADING</a></td> = =09=09=09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09= =09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table> = =09=09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09= =09</tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09= =09=09</table> =09=09=09=09=09=09=09=09=09<!--Current Offerings Button-->= =09=09=09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cell= spacing=3D"0" class=3D"mobile-button-container" role=3D"presentation" width= =3D"100%"> =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09= =09=09=09=09<tr> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center"= class=3D"padding-copy" style=3D"padding: 0 0 10px 0;"> =09=09=09=09=09= =09=09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0= " class=3D"responsive-table" role=3D"presentation"> =09=09=09=09=09=09=09= =09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09=09=09=09<tr>= =09=09=09=09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center"><a cla= ss=3D"mobile-button" href=3D"https://go.primarymarkets.com/e/279962/current= -offerings/jykqx/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y"= pardot-region=3D"button" style=3D"font-size: 12px; font-family: Calibri,sa= ns-serif; font-weight: bold; color: #ffffff; text-decoration: none; backgro= und-color: #00b366; border-top: 10px solid #00b366; border-bottom: 10px sol= id #00b366; border-left: 35px solid #00b366; border-right: 35px solid #00b3= 66; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px= ; display: inline-block;" target=3D"_blank">CAPITAL RAISES</a></td> =09= =09=09=09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09= =09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09=09=09=09</table> =09= =09=09=09=09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09<= /tr> =09=09=09=09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09= </table> =09=09=09=09=09=09=09=09=09<!--Unicorn Button--> =09=09=09= =09=09=09=09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" c= lass=3D"mobile-button-container" role=3D"presentation" width=3D"100%"> = =09=09=09=09=09=09=09=09=09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09<t= r> =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center" class=3D"padd= ing-copy" style=3D"padding: 0px 0 40px 0;"> =09=09=09=09=09=09=09=09=09= =09=09=09<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" class=3D"r= esponsive-table" role=3D"presentation"> =09=09=09=09=09=09=09=09=09=09=09= =09=09<tbody> =09=09=09=09=09=09=09=09=09=09=09=09=09=09<tr> =09=09=09= =09=09=09=09=09=09=09=09=09=09=09=09<td align=3D"center"><a class=3D"mobile= -button" href=3D"https://go.primarymarkets.com/e/279962/buy-shares-in-unico= rns/jykqz/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" pardot= -region=3D"button" style=3D"font-size: 12px; font-family: Calibri,sans-seri= f; font-weight: bold; color: #ffffff; text-decoration: none; background-col= or: #00b366; border-top: 10px solid #00b366; border-bottom: 10px solid #00b= 366; border-left: 51px solid #00b366; border-right: 51px solid #00b366; bor= der-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; displ= ay: inline-block;" target=3D"_blank">UNICORNS</a></td> =09=09=09=09=09=09= =09=09=09=09=09=09=09=09</tr> =09=09=09=09=09=09=09=09=09=09=09=09=09</tb= ody> =09=09=09=09=09=09=09=09=09=09=09=09</table> =09=09=09=09=09=09=09= =09=09=09=09=09</td> =09=09=09=09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09=09=09=09</tbody> =09=09=09=09=09=09=09=09=09</table> =09= =09=09=09=09=09=09=09=09</td> =09=09=09=09=09=09=09=09</tr> =09=09=09= =09=09=09=09</tbody> =09=09=09=09=09=09</table> =09=09=09=09=09=09</td>= =09=09=09=09=09</tr> =09=09=09=09</tbody> =09=09=09</table> =09=09= =09</td> =09=09</tr> =09</tbody> </table> <!-- FOOTER --> <tab= le border=3D"0" cellpadding=3D"0" cellspacing=3D"0" class=3D"content" role= =3D"presentation" width=3D"100%"> =09<tbody> =09=09<tr> =09=09=09<td = align=3D"center" bgcolor=3D"#ffffff" class=3D"section-padding"> =09=09=09= <table align=3D"center" border=3D"0" cellpadding=3D"0" cellspacing=3D"0" cl= ass=3D"responsive-table" role=3D"presentation" width=3D"500"> =09=09=09= =09<tbody> =09=09=09=09=09<tr> =09=09=09=09=09=09<td align=3D"center" c= lass=3D"100p" style=3D"padding-top:20px;padding-bottom:30px;text-align:cent= er;" valign=3D"top" width=3D"640"> =09=09=09=09=09=09<center style=3D"fon= t-family: Calibri,sans-serif;font-size:12px;color:#666;line-height:1.6;padd= ing-top:20px;padding-bottom:30px;text-align:center;"><span style=3D"font-si= ze:14px;color:#000;"><strong>Connect with Us:</strong></span><br> =09=09= =09=09=09=09<br> =09=09=09=09=09=09<a href=3D"https://go.primarymarkets.c= om/e/279962/PrimaryMarkets/jykr2/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1= ALv19VE77rc2J7Y" style=3D"color: #666;text-decoration: none;"><img alt=3D"F= acebook" src=3D"https://storage.pardot.com/279962/192013/facebook.png"></a>= <a href=3D"https://go.primarymarkets.com/e/279962/Primary-Markets/jyk= r4/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" style=3D"colo= r: #666;text-decoration: none;"><img alt=3D"Twitter" src=3D"https://storage= .pardot.com/279962/192017/twitter.png"></a> <a href=3D"https://go.prim= arymarkets.com/e/279962/company-primarymarkets/jykr6/790120519?h=3DxnZ0hvMq= SbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" style=3D"color: #666;text-decoration: = none;"><img alt=3D"LinkedIn" src=3D"https://storage.pardot.com/279962/19201= 5/Linkedin.png"></a><br> =09=09=09=09=09=09<br> =09=09=09=09=09=09<a hr= ef=3D"https://go.primarymarkets.com/e/279962/edium-email-utm-content-footer= /jykr8/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" style=3D"= color: #666;text-decoration: none;"><img src=3D"https://www.primarymarkets.= com/images/2019/logo-primarymarkets-2020.png" width=3D"300"></a><br> =09= =09=09=09=09=09<br> =09=09=09=09=09=09+61 2 9993 4475<br> =09=09=09=09= =09=09<a href=3D"https://go.primarymarkets.com/e/279962/edium-email-utm-con= tent-footer/jykr8/790120519?h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y= " style=3D"color: #666;text-decoration: none;">www.primarymarkets.com</a><b= r> =09=09=09=09=09=09Corporate Authorised Representative: AFSL 334 838<br= > =09=09=09=09=09=09Level 16, 56 Pitt Street, Sydney NSW 2000, Australia<= br> =09=09=09=09=09=09PO Box R697, Royal Exchange NSW 1225, Australia<br>= =09=09=09=09=09=09<br> =09=09=09=09=09=09<small>IMPORTANT LEGAL NOTICE= AND DISCLOSURES: Nothing contained in this email constitutes tax, legal, i= nsurance or investment advice nor does it constitute a solicitation or an o= ffer to buy or sell any security or other financial instrument. This email = and any attachment(s) are intended only for the exclusive use of the addres= see(s) and may contain information that is privileged and confidential. If = you are not the intended recipient, any use, interference with, disclosure = or copying of this material is unauthorised and strictly prohibited. If you= have received this message in error, please notify the sender by return em= ail immediately and delete the message from your computer without making an= y copies. Investing in securities in private companies is speculative and i= nvolves a high degree of risk. The recipient must be prepared to withstand = a total loss of your investment. We strongly encourage the recipient to c= omplete their own independent due diligence before investing in securities = or financial instruments including obtaining additional information, opinio= ns, financial projections and legal or other investment advice. All emails = sent to or from PrimaryMarkets Limited corporate email systems may be retai= ned, monitored and/or reviewed by PrimaryMarkets and its respective personn= el.<br> =09=09=09=09=09=09<br> =09=09=09=09=09=09<a href=3D"https://go.= primarymarkets.com/e/279962/edium-email-utm-content-footer/jykrb/790120519?= h=3DxnZ0hvMqSbU_vROfM7X2xm0ZIWS1ALv19VE77rc2J7Y" style=3D"color: #666;text-= decoration: none;">Terms, Privacy and Legal</a> | <a href=3D"https://go.pri= marymarkets.com/unsubscribe/u/279962/5dff1c304acd87442e0e3cb4b28c05bf8dda3d= e5195055ab75548c39ef116cbe/790120519" style=3D"color: #666;text-decoration:= none;"> <unsubscribe>Unsubscribe</unsubscribe> </a></small></center> =09= =09=09=09=09=09</td> =09=09=09=09=09</tr> =09=09=09=09</tbody> =09=09= =09</table> =09=09=09</td> =09=09</tr> =09</tbody> </table> <img = alt=3D"" src=3D"https://go.primarymarkets.com/r/279962/1/790120519/open/1" = /></body> </html> --_=_swift_v4_1604347796_b6fd3a76287d76c950eb1348638eb95c_=_--
| ver. 1.4 |
Github
|
.
| PHP 7.4.33 | Generation time: 0 |
proxy
|
phpinfo
|
Settings